Shize Biotechnology has completed a Series B/B+ round and a Series C1 round of financing totaling 400 million yuan.

On January 14th, Sizhe Biotech announced the successful completion of consecutive Series B/B+ and C1 rounds of market-driven financing totaling four billion yuan. The Series B/B+ financing was led by Sanofi, with participation from Taolian/Taikun Capital and Kailaiying Pharmaceutical Group, joint investments from Jianfa Emerging Investment, Suzhou Angel Mother Fund, Qisheng Capital, Xinxixi Capital, Tianhui Capital, and additional investments from Peak Ray Capital, Qiming Venture Partners, Lilly Asia Ventures, and Sequoia China; while the C1 round was led by Guoxin Fund, with follow-on investment from Yuyao Gongtou.